当前位置: 首页 > 详情页

Bovine lactoferricin P13 triggers ROS-mediated caspase-dependent apoptosis in SMMC7721 cells

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Anhui Med Univ, Affiliated Prov Hosp, Dept Hepat Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China; [2]Anhui Med Univ, Affiliated Prov Hosp, Anhui Prov Key Lab Hepatopancreatobiliary Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China; [3]Beijing Childrens Hosp Grp, Anhui Prov Childrens Hosp, Dept Gen Surg, Hefei 230051, Anhui, Peoples R China
出处:
ISSN:

关键词: bovine lactoferricin P13 hepatocellular carcinoma apoptosis reactive oxygen species caspase-3 caspase-9

摘要:
Bovine lactoferricin P13 (LfcinB-P13) is a peptide derived from LfcinB. In the present study, the effect of LfcinB-P13 on the human liver cancer cell line SMMC7721 was investigated in vitro and in vivo. The results of the present study indicate that LfcinB-P13 significantly decreased SMMC7721 cell viability in vitro (P=0.032 vs. untreated cells), while exhibiting low cytotoxicity in the wild-type liver cell line L02. In addition, the rate of apoptosis in SMMC7721 cells was significantly increased following treatment with 40 and 60 mu g/ml LfcinB-P13 (P=0.0053 vs. the control group), which was associated with an increase in the level of reactive oxygen species (ROS) and the activation of caspase-3 and-9. Furthermore, ROS chelation led to the suppression of LfcinB-P13-mediated caspase-3 and-9 activation in SMMC7721 cells. LfcinB-P13 was demonstrated to markedly inhibit tumor growth in an SMMC7721-xenograft nude mouse model. The results of the present study indicate that LfcinB-P13 is a novel candidate therapeutic agent for the treatment of liver cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Anhui Med Univ, Affiliated Prov Hosp, Dept Hepat Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China; [2]Anhui Med Univ, Affiliated Prov Hosp, Anhui Prov Key Lab Hepatopancreatobiliary Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China; [3]Beijing Childrens Hosp Grp, Anhui Prov Childrens Hosp, Dept Gen Surg, Hefei 230051, Anhui, Peoples R China
通讯作者:
通讯机构: [1]Anhui Med Univ, Affiliated Prov Hosp, Dept Hepat Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China; [2]Anhui Med Univ, Affiliated Prov Hosp, Anhui Prov Key Lab Hepatopancreatobiliary Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17005 今日访问量:0 总访问量:906 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院